Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2025)

Vir Biotechnology's Gains from Investment Securities history spans 8 years, with the latest figure at -$4.0 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to -$4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.7 million, a N/A change, with the full-year FY2025 number at -$1.7 million, changed N/A from a year prior.
  • Gains from Investment Securities hit -$4.0 million in Q4 2025 for Vir Biotechnology, down from $5.3 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for VIR hit a ceiling of $95.0 million in Q1 2022 and a floor of -$252.2 million in Q4 2022.
  • Historically, Gains from Investment Securities has averaged -$7.1 million across 5 years, with a median of $1.9 million in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 10094.42% in 2022, down 9130.97% in 2022.
  • Tracing VIR's Gains from Investment Securities over 5 years: stood at $91.7 million in 2021, then plummeted by 375.16% to -$252.2 million in 2022, then surged by 100.39% to $993000.0 in 2023, then crashed by 695.67% to -$5.9 million in 2024, then skyrocketed by 32.46% to -$4.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for VIR at -$4.0 million in Q4 2025, $5.3 million in Q3 2025, and $3.4 million in Q2 2025.